+

WO2009033809A3 - Use of a peptide as a therapeutic agent - Google Patents

Use of a peptide as a therapeutic agent Download PDF

Info

Publication number
WO2009033809A3
WO2009033809A3 PCT/EP2008/008151 EP2008008151W WO2009033809A3 WO 2009033809 A3 WO2009033809 A3 WO 2009033809A3 EP 2008008151 W EP2008008151 W EP 2008008151W WO 2009033809 A3 WO2009033809 A3 WO 2009033809A3
Authority
WO
WIPO (PCT)
Prior art keywords
gly
val
disease
leu
lys
Prior art date
Application number
PCT/EP2008/008151
Other languages
French (fr)
Other versions
WO2009033809A2 (en
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Laboratories Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories Ag filed Critical Mondobiotech Laboratories Ag
Publication of WO2009033809A2 publication Critical patent/WO2009033809A2/en
Publication of WO2009033809A3 publication Critical patent/WO2009033809A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the use of the combination of the peptide compounds Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys- Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 and Tyr-Gly-Gly-Phe- Leu-Arg-Lys-Tyr-Pro-Lys-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
PCT/EP2008/008151 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent WO2009033809A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017749 2007-09-11
EP07017765.4 2007-09-11
EP07017765 2007-09-11
EP07017749.8 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033809A2 WO2009033809A2 (en) 2009-03-19
WO2009033809A3 true WO2009033809A3 (en) 2009-10-01

Family

ID=40452593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008151 WO2009033809A2 (en) 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent

Country Status (1)

Country Link
WO (1) WO2009033809A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
CN1674919A (en) 2002-08-12 2005-09-28 比克尔·斯韦恩森 Application of CGRP antagonist compounds in the treatment of psoriasis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
WO2002092018A2 (en) * 2001-05-16 2002-11-21 Plotnikoff Nicholas P Methods for inducing sustained immune response
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2005081619A2 (en) * 2003-11-20 2005-09-09 Neuronova Ab Compounds and methods for increasing neurogenesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
WO2002092018A2 (en) * 2001-05-16 2002-11-21 Plotnikoff Nicholas P Methods for inducing sustained immune response
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2005081619A2 (en) * 2003-11-20 2005-09-09 Neuronova Ab Compounds and methods for increasing neurogenesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ICHINOSE M ET AL: "ENHANCEMENT OF PHAGOCYTOSIS BY DYNORPHIN A IN MOUSE PERITONEAL MACROPHAGES", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 60, no. 1/02, 1 July 1995 (1995-07-01), pages 37 - 43, XP002950298, ISSN: 0165-5728 *
MA WEIYA ET AL: "Increased calcitonin gene-related peptide in neuroma and invading macrophages is involved in the up-regulation of interleukin-6 and thermal hyperalgesia in a rat model of mononeuropathy.", JOURNAL OF NEUROCHEMISTRY JUL 2006, vol. 98, no. 1, July 2006 (2006-07-01), pages 180 - 192, XP002534444, ISSN: 0022-3042 *
WANG HONGCHENG ET AL: "Production and secretion of calcitonin gene-related peptide from human lymphocytes.", JOURNAL OF NEUROIMMUNOLOGY SEP 2002, vol. 130, no. 1-2, September 2002 (2002-09-01), pages 155 - 162, XP002534445, ISSN: 0165-5728 *

Also Published As

Publication number Publication date
WO2009033809A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (en) Use of a peptide as a therapeutic agent
WO2009033797A3 (en) Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
WO2009043518A3 (en) Use of a combination of cart peptides as a therapeutic agent
HUS1500034I1 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
WO2009033813A3 (en) Use of a peptide as a therapeutic agent
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2009033818A3 (en) Use of a peptide as a therapeutic agent
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
WO2009033820A3 (en) Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2009043523A3 (en) Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
WO2009046876A3 (en) Use of a peptide as a therapeutic agent
WO2009043519A3 (en) Use of band 3 protein and pacap-27 as a therapeutic agent
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2008009426A9 (en) 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
WO2009046872A3 (en) Use of a peptide as a therapeutic agent
WO2009033812A3 (en) Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
WO2009033815A3 (en) Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent
WO2009046880A3 (en) Use of a peptide as a therapeutic agent
WO2009043521A3 (en) Use of urocortin iii and urocortin i as therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802619

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802619

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载